670P Cabozantinib associated with concomitant radiotherapy or a bone targeted agent (multimodal approach, results from the CABOREAL study post-hoc analysis)

Abstract

Cabozantinib (Cabo) is approved in Europe for the treatment of patients (pts) with metastatic renal cell carcinoma (mRCC) in treatment-naïve adults with intermediate or poor risk or following prior VEGF-targeted therapy. CABOREAL describes the use of Cabo in a real-world setting (RWS) in the largest unselected population to date of pts with mRCC who received at least one dose of Cabo. We report here, the use and the activity of Cabo in subgroup of pts who received concomitant radiotherapy (cRT) or concomitant bone targeted agents (cBTA).